he co-founded in April 2016. Prior to Fairmount, Mr. Kiselak was a managing director at RA Capital Management, LLC, a healthcare and life science
investment firm. Mr. Kiselak also serves as a director for several private companies. He received his bachelors degree in Neuroscience and Economics from Amherst College.
We believe Mr. Kiselak is qualified to serve on our Board because of his experience advising biotechnology companies and as a manager of funds
specializing in the area of life sciences.
Jennifer K. Moses. Ms. Moses has served as a member of our Board since July 2021.
Ms. Moses has served as Chief Financial Officer of G1 Therapeutics, Inc. (Nasdaq: GTHX), a biopharmaceutical company, since May 2019, and she previously served as its Vice President of Finance and Accounting from March 2015 to
May 2019. Prior to joining G1, Ms. Moses was a Partner at Rankin McKenzie, LLC, a financial consulting company, from 2007 to 2015, where she served as Acting Chief Financial Officer and Controller for venture-backed companies. Prior
to joining Rankin McKenzie, Ms. Moses held roles of increasing responsibility at Deloitte, a professional services company, including providing tax services to clients and later focusing on strategic planning and internal communications in the
Office of the Chief Executive Officer of Deloitte Tax. Ms. Moses received a B.S. in Accounting from The Pennsylvania State University and is a C.P.A.
We believe Ms. Moses is qualified to serve on our Board because of her financial expertise and experience within the biopharmaceutical industry.
Class III Directors Continuing in Office
Jonathan Violin, Ph.D. Dr. Violin has served as our President, Chief Executive Officer and member of our Board since January 2021,
and he previously served as our President and Chief Operating Officer from October 2020 until January 2021. He was the Co-Founder of Private Viridian and led Private Viridians operations from April 2020
to its acquisition. Prior to that, Dr. Violin co-founded Dianthus Therapeutics, Inc., a biotechnology company, in May 2019. He also co-founded Quellis Biosciences,
Inc., a biotechnology company (acquired by Astria Therapeutics, Inc. (Nasdaq: ATXS), formerly Catabasis Pharmaceuticals, Inc.), in 2018 and since January 2021, has served on the Astria Therapeutics board of directors. Prior to that, he co-founded and helped lead Trevena Inc. (Nasdaq: TRVN), a biotechnology company, in various roles from 2008 until November 2018, including most recently as Senior Vice President, Scientific Affairs and Investor
Relations Officer. Dr. Violin received a Ph.D. from the Department of Pharmacology Biomedical Sciences Program at the University of California, San Diego, a M.B.A. with a concentration in Health Sector Management from the Fuqua School of
Business at Duke University, and a B.S. in Chemical Pharmacology from Duke University.
We believe that Dr. Violin is qualified to serve on our Board
because of his unique perspective from his role as our Chief Executive Officer, prior role as Chief Operating Officer and extensive experience and innovations in the field of biotechnology. In addition, Dr. Violins academic expertise and
accomplishments provide the Board with in-depth product and field knowledge.
Arlene M. Morris.
Ms. Morris has served as a member of our Board since January 2018. Ms. Morris has served as Chief Executive Officer at Willow Advisors, LLC, a consultancy advising biotech companies on financing, strategy and business development,
since May 2015. From April 2012 until May 2015, Ms. Morris served as the Chief Executive Officer of Syndax Pharmaceuticals, Inc., a privately-held oncology company focused on the development and commercialization of therapies for
treatment-resistant cancers. She also served as a member of the Syndax Pharmaceuticals board of directors from 2011 to 2015. From 2003 to 2011, Ms. Morris served as President, Chief Executive Officer and a member of the board of directors of
Affymax, Inc. (OTCMKTS: AFFY), a biotechnology company. Ms. Morris also held various management and executive positions at Clearview Projects, Inc., a corporate advisory firm; Coulter Pharmaceutical, Inc., a pharmaceutical company; Scios Inc.,
a biopharmaceutical company; and Johnson & Johnson (NYSE: JNJ), a healthcare company. She is currently a member of the board of directors of Viveve Medical, Inc. (Nasdaq: VIVE), a medical device company; Palatin Technologies, Inc. (NYSE:
PTN), a biopharmaceutical company; and Cogent Biosciences, Inc.
8